Literature DB >> 19789348

Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Sook Shin1, Tae-Dong Kim, Fang Jin, Jan M van Deursen, Scott M Dehm, Donald J Tindall, Joseph P Grande, Jan-Marie Munz, George Vasmatzis, Ralf Janknecht.   

Abstract

ETS variant 1 (ETV1), also known as ETS-related protein 81, is overexpressed in prostate tumors, but whether and how this transcription factor affects tumorigenesis has remained elusive. Here, we show that ETV1 is primarily overexpressed in the most aggressive human prostate tumors. Transgenic ETV1 mice developed prostatic intraepithelial neoplasia as well as hyperplasia/neoplasia in seminal vesicles. Moreover, ETV1 cooperated with the androgen receptor (AR) to bind to the prostate-specific antigen enhancer and stimulate gene transcription. Consistent with its ability to physically interact with AR, ETV1 rendered an ETV1 binding site-driven reporter androgen inducible, and, on the other hand, ETV1 super-induced transcription from an AR binding site on androgen stimulation. In conclusion, our study substantiates that ETV1 overexpression is an underlying cause in the development of prostate and possibly also seminal vesicle cancer. Its interaction with and activation of AR provides a molecular mechanism on how ETV1 exerts its deleterious function. Thus, inhibiting ETV1 or blocking its interaction with AR may represent novel strategies in prostate cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789348      PMCID: PMC3947560          DOI: 10.1158/0008-5472.CAN-09-0941

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex.

Authors:  Maggie C Louie; Hong Qiong Yang; Ai-Hong Ma; Wei Xu; June X Zou; Hsing-Jien Kung; Hong-Wu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

2.  Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor.

Authors:  Basem S Goueli; Ralf Janknecht
Journal:  Oncogene       Date:  2003-09-11       Impact factor: 9.867

3.  Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu.

Authors:  Apollina Goel; Ralf Janknecht
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

4.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

5.  HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81.

Authors:  Sean C Dowdy; Andrea Mariani; Ralf Janknecht
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

6.  p300 in prostate cancer proliferation and progression.

Authors:  Jose D Debes; Thomas J Sebo; Christine M Lohse; Linda M Murphy; De Anna L Haugen; Donald J Tindall
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

7.  Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1).

Authors:  Ralf Janknecht
Journal:  Oncogene       Date:  2003-02-06       Impact factor: 9.867

8.  Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A.

Authors:  Jianmin Wu; Ralf Janknecht
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

Review 9.  Biology of prostate-specific antigen.

Authors:  Steven P Balk; Yoo-Joung Ko; Glenn J Bubley
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

10.  Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.

Authors:  V J Gnanapragasam; H Y Leung; A S Pulimood; D E Neal; C N Robson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

View more
  44 in total

1.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

2.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

3.  Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.

Authors:  Yu Chen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 4.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

Review 5.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

6.  Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.

Authors:  Jake Higgins; Michele Brogley; Nallasivam Palanisamy; Rohit Mehra; Michael M Ittmann; Jun Z Li; Scott A Tomlins; Diane M Robins
Journal:  Horm Cancer       Date:  2015-01-29       Impact factor: 3.869

7.  ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain.

Authors:  Simon L Currie; Jedediah J Doane; Kathryn S Evans; Niraja Bhachech; Bethany J Madison; Desmond K W Lau; Lawrence P McIntosh; Jack J Skalicky; Kathleen A Clark; Barbara J Graves
Journal:  J Mol Biol       Date:  2017-07-17       Impact factor: 5.469

8.  Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.

Authors:  Tae-Dong Kim; James R Fuchs; Eric Schwartz; Dalia Abdelhamid; Jonathan Etter; William L Berry; Chenglong Li; Michael A Ihnat; Pui-Kai Li; Ralf Janknecht
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

9.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

10.  ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.

Authors:  Sook Shin; Sangphil Oh; Seayoon An; Ralf Janknecht
Journal:  Oncol Rep       Date:  2012-10-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.